Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials

Abstract

BACKGROUND To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. RESULTS Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively.Bevacizumab increased the… (More)
DOI: 10.18632/oncotarget.6507

Topics

5 Figures and Tables

Slides referencing similar topics